Advertisement
Collaboration › Details
Medigene–Leucadia: investor conference, 201906 supply service Medigene presents at Jefferies Global Healthcare Conference NY
Period | 2019-06-04 � 2019-06-07 | |
Region | New York, NY | |
Country | United States (USA) | |
Partner, 1st | Medigene AG (FSE: MDG1, Prime Standard) | |
Group | Medigene (Group) | |
Partner, 2nd | Jefferies LLC | |
Group | Leucadia (Group) | |
Product | Jefferies 2019 Global Healthcare Conference New York | |
Product 2 | TCR engineered T-cells | |
Person | Schendel, Dolores J. (Medigene 202207– CSO + Head of RnD before CEO + CMO + Triant + HelmholtzZentrum München) | |
Person 2 | Hofmann, Julia (ITM 202110– Head of Corp Comms before MC Services + Medigene) | |
Medigene AG. (5/8/19). "Press Release: Medigene Participates at Upcoming Conferences". Martinsried.
Medigene AG (FSE: MDG1, Prime Standard) today announced its participation at the following upcoming scientific, business development and investor conferences:
EACR-ESMO Joint Conference on Liquid Biopsies
Date: 15 - 17 May 2019
Location: Bergamo, Italy
CIMT Annual Meeting
Date: 21 - 23 May 2019
Location: Mainz, Germany
Prof. Dolores J. Schendel, CEO of Medigene AG, will give a presentation on the topic "Matching future needs for world patient populations needing TCR-T therapies with different antigen specificities and HLA restrictions" on 23 May.
ASCO - American Society of Clinical Oncology - Annual Meeting
Date: 01 - 05 June 2019
Location: Chicago, USA
BIO International Convention
Date: 03 - 06 June 2019
Location: Philadelphia, USA
Jefferies Global Healthcare Conference
Date: 04 - 07 June 2019
Location: New York/USA
Prof. Dolores J. Schendel, CEO of Medigene AG, is invited to give a company presentation.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com
Record changed: 2022-11-19 |
Advertisement
More documents for Medigene (Group)
- [1] Medigene AG. (11/21/23). "Press Release: Medigene AG Announces Prioritization of Pipeline and Resource Allocation as Well as Extension of Cash Runway". Planegg....
- [2] Medigene AG. (5/3/23). "Press Release: Medigene AG Reports Financial Results and Business Update for Q1 2023". Martinsried....
- [3] Medigene AG. (5/2/23). "Press Release: Medigene Acquires Worldwide, Exclusive License of CD40L-CD28 Costimulatory Switch Receptor". Planegg....
- [4] Medigene AG. (2/1/23). "Press Release: Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications". Planegg....
- [5] Medigene AG. (1/18/23). "Press Release: Medigene Receives $3 Million Milestone Payment from 2seventy bio". Planegg....
- [6] Medigene AG. (2/25/22). "Press Release: Dr. Selwyn Ho Appointed New CEO of Medigene". Lisbon....
- [7] BioNTech SE. (2/21/22). "Press Release: BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer". Mainz & Martinsried....
- [8] Medigene AG. (1/28/21). "Press Release: Focus on Solid Tumors – Discontinuation of MDG1021 Development Program". Planegg-Martinsried....
- [9] Medigene AG. (1/13/21). "Press Release: Medigene Expands Patent Protection of Its Technologies in Key Markets, the USA and Europe". Planegg-Martinsried....
- [10] Medigene AG. (11/12/20). "Press Release: Medigene Provides Q3 2020 Update". Planegg-Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top